Mapi Research Trust
Mapi Research Trust is a French non-profit that facilitates global access to Clinical Outcome Assessments (COAs) through its ePROVIDE platform, exclusively distributing 800+ COAs and serving pharmaceutical, academic, and healthcare customers in clinical research.
- Company typePrivate
- Founded1995
- HeadquartersLeopardstown, Ireland
- Headcount51–100
- GTM typeB2B
- OfferingServices
What Mapi Research Trust does
Mapi Research Trust is a French-registered non-profit organization founded in 1995 and headquartered in Lyon, with an additional office in Leopardstown, Ireland, that facilitates global access to Clinical Outcome Assessments (COAs). The organization's mission centers on improving patients' quality of life by collecting, curating, and distributing patient-centered outcome information on behalf of questionnaire developers and copyright holders, with 30+ years of accumulated expertise in the field. It operates as an ICON business under the governance of ICON Clinical Research Limited (the publicly traded parent ICON plc) while maintaining an independent non-profit status.
The core technology is the ePROVIDE online platform, which centralizes three proprietary databases — PROQOLID (9,000+ COAs described in detail, the largest such catalog), PROLABELS (2,400+ label claims documenting how patient-reported outcomes have been incorporated into drug approvals), and PROINSIGHT (300+ regulatory guidelines) — alongside COA licensing, translation and linguistic validation, eCOA migration and certification, targeted literature review (Patient-Centered Endpoint Intelligence), and a COA Repository workspace. Mapi Research Trust is the exclusive distributor for 800+ COAs and supports multi-decade partnerships with Wiley, Springer Nature, GL Assessment, MSD/Merck Sharp & Dohme, the PANSS Institute, Observia, WCG, and numerous academic institutions and patient advocacy organizations.
Revenue is generated primarily through COA licensing fees (both royalty fees for copyrighted COAs and service fees for public-domain COAs), translation and linguistic validation projects, eCOA migration and certification services, and targeted literature reviews, with quote-based per-transaction pricing for commercial sponsors and healthcare organizations. A freemium tier provides free access for non-funded academic researchers and reduced fees for funded academics, which supports a network of 3,500+ researchers and health-authority representatives and processes 20,000+ information requests per year. Primary customer segments are pharmaceutical and biotech sponsors of clinical trials, academic and independent researchers, healthcare organizations and hospitals, and rare-disease researchers.
Mapi Research Trust firmographics
Firmographics- Name
- Mapi Research Trust
- Legal name
- Mapi Research Trust
- Website
- https://mapi-trust.org
- Company type
- Private
- Founded year
- 1995
- Operating status
- Operating
- Headcount range
- 51–100 employees
- Short description
- Mapi Research Trust is a French non-profit that facilitates global access to Clinical Outcome Assessments (COAs) through its ePROVIDE platform, exclusively distributing 800+ COAs and serving pharmaceutical, academic, and healthcare customers in clinical research.
- Ownership category
- akta.pro rank
Mapi Research Trust industry classification
Industry- Product category
- Clinical Outcome Assessments (COA)
- NAICS
- Scientific Research and Development Services (5417)
- SIC
- Services-Commercial Physical & Biological Research (8731)
- akta.pro primary industry
- Clinical Trial Site Operations & Study Coordination (HLAGACAE)
- akta.pro secondary industries
- Clinical Quality Assurance (GCP QA, TMF/QMS oversight) (HLAGAKAI), Consent, Preference & Data Rights Management (incl. HIPAA/GDPR support) (HLACAIAG)
Keywords
Where Mapi Research Trust is headquartered
LocationHeadquarters
- HQ city
- Leopardstown
- HQ country
- Ireland
- HQ region
- Europe
Offices1 record
Markets served
Mapi Research Trust business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
Revenue model
- COA Licensing Services: Fees for licensing COAs for use in clinical trials, including access to official original versions, validated translations, scoring methods, and interpretation guidance. Both copyrighted COAs (royalty and service fees) and public domain COAs (service fees) incur charges.
- Academic Access - Free Tier: Free access to all COAs from the distribution catalog (original versions, translations, and electronic versions) for non-funded academic researchers. Funded academic researchers benefit from reduced fees.
- Translation and Linguistic Validation Services: Coordination of translation projects for COAs requiring linguistic validation to ensure measurement property equivalence across languages
- eCOA Licensing and Implementation Services: Services for digitization of paper COAs including best practice guidance, screenshot review and certification, and expert review for electronic capture of data
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Freemium | Others | Academic (Non-funded researchers) |
| Subscription | Per transaction | Academic (Funded researchers) |
| Subscription | Per transaction | Commercial/Sponsor Use |
| Subscription | Per transaction | Healthcare Organizations/Hospitals |
Go-to-market motion1 record
Distribution channels4 records
Marketing channels7 records
Mapi Research Trust product offering
Product offeringCore offering
Mapi Research Trust is a non-profit organization that facilitates access to Clinical Outcome Assessments (COAs) by serving as the exclusive distributor for 800+ COAs on behalf of copyright holders and developers. Through its centralized ePROVIDE™ platform, it provides COA licensing, translation and linguistic validation, eCOA digitization and certification, and patient-centered endpoint intelligence (targeted literature reviews) to pharmaceutical sponsors, academic researchers, and healthcare organizations worldwide.
Product overview
Mapi Research Trust is a non-profit organization offering a comprehensive portfolio of COA (Clinical Outcome Assessment) services through its centralized ePROVIDE™ platform. The portfolio consists of three interconnected databases (PROQOLID™ with 9,000+ COA descriptions, PROLABELS™ with 2,400+ label claims, and PROINSIGHT™ with 300+ regulatory guidelines) alongside core services including COA Licensing (streamlined licensing for any COA), Patient-Centered Endpoint Intelligence (targeted literature reviews for endpoint selection), Translation and Linguistic Validation, eCOA Licensing (digitization and certification), and COA Repository. Mapi Research Trust serves as the exclusive distributor of 800+ COAs, managing distribution, licensing, and protection of questionnaire assets on behalf of developers and copyright holders.
Differentiator
Problem solved
Functional benefit
Brands
- ePROVIDE: Online platform providing access to COA databases and services including PROQOLID, PROLABELS, and PROINSIGHT
- PROQOLID
- PROLABELS
- PROINSIGHT
Products and services
- ePROVIDE™
Quantifiable outcome
- Streamlined licensing reduces burden for sponsors through single point of contact
- +2 more outcomes
Companies that use Mapi Research Trust
Customer profileNamed customers6 records
Segments4 records
Ideal customer profiles5 records
Mapi Research Trust technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature5 records
Mapi Research Trust partnerships and signals
Strategic signalPartnerships
21 partnerships are on record, tiered minor, core and flagship.
- Université LavalminorUniversité Laval entrusted MRT with management of their COAs including the Fear of Cancer Recurrence Inventory (FCRI) and FCRI-SF.
- Université de Montréal and Institut universitaire de gériatrie de MontréalminorAcademic institutions entrusted MRT with management of the QUEST 2.0 questionnaire for measuring user satisfaction with assistive technologies.
- Dr. Jesse CedarbaumminorDr. Cedarbaum works with MRT to manage distribution of the ALSFRS-R (Amyotrophic Lateral Sclerosis Functional Rating Scale - Revised) for evaluating disability progression in ALS patients.
- Friedreich's Ataxia Research Alliance (FARA)minorFARA entrusted MRT with management of 5 COAs developed for Friedreich's ataxia, a rare genetic and progressive neuromuscular disease affecting approximately 15,000 individuals worldwide.
- PANSS InstitutecoreAuthors of the PANSS (Positive and Negative Syndrome Scale for Schizophrenia) appointed MRT as their exclusive licensing and distribution partner.
- QOL Technologies Ltd.corePartnership for management of QOL Technologies' COAs. All requests for use are sent directly to Mapi Research Trust via the ePROVIDE platform.
- South London and Maudsley NHS Foundation TrustcoreNHS Foundation Trust entrusted MRT with exclusive distribution and licensing of the SDS-Gossop and SOWS-Gossop questionnaires.
- Professor Ewa Roos (University of Southern Denmark)coreProfessor Roos entrusted MRT with management of the KOOS, HOOS, FAOS and their derivatives. These are gold standard instruments in joint injury and osteoarthritis assessment, developed over 20 years ago and widely used in clinical trials.
- Springer NaturecorePartnership for distribution of Clinical Outcome Assessments and management of licensing requests. MRT brings 30 years of experience to manage all licensing requests and support COA users with appropriate information and essential materials for proper use.
- Merck Sharp & Dohme LLC (MSD)coreMRT serves as exclusive partner for licensing and distribution of MSD's COA measures including management of translations and electronic versions. Joint development of MSD's dedicated COA website (msdpatientmeasures.com).
- ObserviacoreExclusive partnership for licensing and distribution of the SPUR (context of clinical research not located in Greater China) Adherence Profiling Tool.
- WCG Clinical Endpoint SolutionscoreMRT supports WCG in the development of 27 electronic versions (eCOA) of Clinical Outcome Assessments for their eCOA library.
- SKEZIminorPartnership to accelerate acquisition and sharing of health data from patients for use in clinical research and routine care settings.
- WileyflagshipLongstanding partnership for distribution of 45 COAs whose rights are managed by Wiley on behalf of professional societies. MRT supports distribution of questionnaires and manages all user requests to access original COAs, scoring guides, validated translations, and electronic versions.
- Orphanet-INSERM / ERICA ConsortiumflagshipEU-funded 4-year grant partnership (European Rare disease research Coordination and Support Action) to analyze and code functional consequences of rare diseases and identify validated COAs that measure functional impacts. MRT provides expertise in identifying appropriate measurement instruments for rare disease research.
- ICON Language ServicescoreCollaboration for coordination of translation projects, ensuring rigorous linguistic validation processes for COA translations to maintain measurement property equivalence across languages.
- ICON plccoreMRT is an ICON business and not-for-profit organization registered under French law. ICON provides governance and infrastructure support while MRT maintains independent operations focused on its mission.
- GL AssessmentminorPartnership for management of COAs developed by GL Assessment.
- InflexxionminorExclusive licensing and distribution agreement for Inflexxion's scales.
- Center for Environmental TherapeuticsminorMRT is exclusive distributor of CET's scales.
- Philip Morris InternationalminorMRT provides access to the ABOUT™-Toolbox, a portfolio of self-report instruments for tobacco and nicotine product assessment developed in collaboration with Philip Morris International.
Scale indicators7 records
Recent moves6 records
Expansion highlights5 records
Mapi Research Trust competitors and assessment
Company assessmentBroad incumbents
- IQVIA: IQVIA offers eCOA and patient-reported outcome services within its broader CRO platform and competes with MRT on regulatory-grade COA selection, licensing, and translation services for global pharma sponsors.
- Medidata (Dassault Systèmes): Medidata's Patient Cloud and Rave EDC ecosystem host and license eCOA instruments at scale. Its instrument library positioning is an adjacent substitute for sponsors that prefer platform-native COA sourcing over a distributor like MRT.
- Clario (formerly CRF Health / ERT): Clario is the largest eCOA platform provider, building proprietary instrument libraries and licensing relationships with COA developers. Its eCOA solutions compete with MRT's eCOA licensing, certification, and digitization services within the same pharmaceutical sponsor workflow.
- Signant Health: Signant Health provides a full eCOA suite (Build, Drive, TrialMax) and licenses its own and third-party instruments, competing with MRT on electronic implementation of patient-reported outcomes in regulated clinical trials.
Direct peers
- Critical Path Institute (C-Path): C-Path develops and stewards qualified Clinical Outcome Assessments and biomarker tools, and runs PRO consortia that compete with MRT's role as a long-term custodian and licensor of disease-specific COAs for regulatory use.
- WCG (WCG Clinical Endpoint Solutions): WCG develops eCOA libraries in collaboration with MRT (27 electronic versions as of 2022) but also originates and licenses COAs independently, serving as both a partner and a partial competitor for sponsor endpoint strategies.
- FACITtrans: FACIT.org operates FACITrans, one of the principal translation and linguistic-validation providers for Clinical Outcome Assessments, competing head-to-head with Mapi Research Trust on cross-language COA adaptation services for pharma sponsors.
Emerging players
- Clinical Ink: Clinical Ink builds electronic Clinical Outcome Assessment (eCOA) and patient-centric data capture tools, competing for the same digitization business that feeds MRT's eBooklets and eCOA licensing services.
Regional players
- Vector Oncology: Vector Oncology provides PRO measurement and COA development services focused on oncology trials, partially overlapping with Mapi Research Trust's CAT/FDA-PRO work in cancer endpoints such as the Fear of Cancer Recurrence Inventory licensed from Université Laval.
Others
- Pharmaprojects / Citeline: Citeline and similar data/analytics vendors track COA usage across clinical trials, creating pipeline-intelligence products. While not a direct competitor, they overlap thematically as repositories and reference layers for trial endpoints.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat6 records
Key risks5 records
Key highlights6 records
Customer concentration
Mapi Research Trust social profiles
Digital presenceMapi Research Trust financial estimates
Financial estimateRevenue estimate
Valuation estimate
Mapi Research Trust leadership team
Management profileNumber of profiles
Profiles4 records
Mapi Research Trust funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Mapi Research Trust M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Mapi Research Trust
What does Mapi Research Trust do?
Mapi Research Trust is a non-profit organization that facilitates access to Clinical Outcome Assessments (COAs) by serving as the exclusive distributor for 800+ COAs on behalf of copyright holders and developers. Through its centralized ePROVIDE™ platform, it provides COA licensing, translation and linguistic validation, eCOA digitization and certification, and patient-centered endpoint intelligence (targeted literature reviews) to pharmaceutical sponsors, academic researchers, and healthcare organizations worldwide.
Is Mapi Research Trust a public or private company?
Mapi Research Trust is a private company. It is classified as corporate owned and is currently operating.
When was Mapi Research Trust founded?
Mapi Research Trust was founded in 1995. It employs 51 to 100 people.
Where is Mapi Research Trust based?
Mapi Research Trust is headquartered in Leopardstown, Ireland, in the Europe region.
How does Mapi Research Trust make money?
Four revenue lines are on record. COA Licensing Services are the primary driver. The others are academic Access - Free Tier, translation and Linguistic Validation Services and eCOA Licensing and Implementation Services.
Who are Mapi Research Trust's main competitors?
Broad incumbents on record are IQVIA, Medidata (Dassault Systèmes), Clario (formerly CRF Health / ERT) and Signant Health. Direct peers are Critical Path Institute (C-Path), WCG (WCG Clinical Endpoint Solutions) and FACITtrans. Clinical Ink is listed as an emerging player. Vector Oncology is listed as a regional player. Pharmaprojects / Citeline is listed as an others.
Does Mapi Research Trust have an API?
No public API is recorded for Mapi Research Trust.
What industry is Mapi Research Trust in?
Mapi Research Trust's product category is Clinical Outcome Assessments (COA). Its primary akta.pro industry code is HLAGACAE, Clinical Trial Site Operations & Study Coordination, with a secondary code of HLAGAKAI, Clinical Quality Assurance (GCP QA, TMF/QMS oversight). Its NAICS code is 5417 and its SIC code is 8731.